Original Blog Summary:
- Pixelgen Technologies, based in Stockholm, Sweden, received a grant and equity financing of $14.7M from the European Innovation Council (EIC) Accelerator.
- The funding will be used to expand the applications of Pixelgen Proxiome Kit, the first kit and software for protein interactome analysis of single cells at high capacity.
- The company specializes in cell-to-cell interactions and tissue, offering researchers new insights into disease mechanisms, drug response, biomarker discovery, and more.
Rewritten Article:
Pixelgen Technologies Receives $14.7M Funding from EIC Accelerator
Pixelgen Technologies, a pioneering company based in Stockholm, Sweden, has recently secured a substantial grant and equity financing amounting to $14.7M from the European Innovation Council (EIC) Accelerator. This funding injection marks a significant milestone for the company as it propels forward in its mission to revolutionize the field of cell-to-cell interactions and tissue applications.
Expanding the Reach of Pixelgen Proxiome Kit
With the newly acquired funds, Pixelgen Technologies is set to expand the applications of its innovative Pixelgen Proxiome Kit. Launched earlier this year, this cutting-edge kit and software solution enables researchers to delve into the intricate world of protein interactome analysis within single cells at an unprecedented level of capacity. By leveraging this technology, scientists can gain invaluable insights into disease mechanisms, drug response, biomarker discovery, and more across various research domains such as cancer, hematology, immunology, and cell therapy.
Revolutionizing Protein Interactomics with Proximity Network Assay
At the core of Pixelgen Technologies’ offerings lies the proprietary Proximity Network Assay, a groundbreaking technology that facilitates nanoscale spatial analysis of immune cell proteins at scale. Recently showcased on BioRxiv, this assay opens up new avenues for researchers to explore the intricate web of cellular interactions with unprecedented detail and precision.
Pixelgen Technologies, under the leadership of CEO Simon Fredriksson, has garnered support from leading investors such as Industrifonden, Sweden’s venture capital fund, and Navigare Ventures. This backing underscores the industry’s confidence in the company’s vision and technology, positioning Pixelgen Technologies as a key player in driving innovation within the realm of cell-to-cell interactions and tissue applications.
Stay tuned for more updates on Pixelgen Technologies’ groundbreaking advancements in the field of single-cell analysis and protein interactomics.
